Evkeeza® (evinacumab) phase 3 trial demonstrates 48% ldl-c reduction in children with ultra-rare form of high cholesterol

Tarrytown, n.y. , may 21, 2022 /prnewswire/ -- children already on other lipid-lowering therapies entered the trial with dangerously high ldl-c (264 mg/dl on average), and 79% saw their ldl-c reduced by at least half at 24 weeks fda submission planned by end of 2022 regeneron pharmaceuticals, inc. (nasdaq: regn) today announced positive results from a phase 3 trial evaluating evkeeza® (evinacumab) in children aged 5 to 11 with homozygous familial hypercholesterolemia (hofh).
REGN Ratings Summary
REGN Quant Ranking